Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in ...

It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

This is the AGAVE-201 trial [NCT04710576]. It was a phase 2 randomized trial, and they looked at 3 different dosing schedules ...